Last updated: May 21, 2026
Isovue-128 clinical trials update, market analysis, and exclusivity projection (iopamidol injection, 128 mg I/mL)
Executive summary: Isovue-128 (iopamidol injection, 128 mg iodine/mL) is an iodinated contrast agent used for CT and angiographic procedures. Commercial trajectory is driven by hospital purchasing cycles and payer contracting rather than late-stage pipeline dynamics. Publicly accessible, trial-level updates for Isovue-128 itself are sparse, while the competitive risk is dominated by other iodinated contrast brands and generic iopamidol formulations. Patent and regulatory exclusivity are largely matured; market projections therefore hinge on supply stability, contracting, and potential substitution to lower-cost equivalents rather than imminent exclusivity expirations.
Scope note: This write-up covers clinical-trials visibility, market structure, and forward-looking market sizing logic for Isovue-128 (not broader “iodinated contrast” as a category). Where public sources do not provide Isovue-128-specific endpoints or trial status, the analysis uses observable regulatory and competitive facts tied to iopamidol contrast products.
Isovue-128 clinical trials update: what phase studies exist and what endpoints matter?
Direct Isovue-128 trial pipeline visibility: Public clinical trials records for “iopamidol” include comparative studies for iodinated contrast agents (type, concentration, osmolality), protocol imaging workflows, and adverse event endpoints. However, Isovue-128-specific registration details (product-level NDC tied to trials) are often not explicit in trial registries and study publications, which limits precision on “Isovue-128-specific” enrollment and outcomes.
What endpoints dominate for iopamidol contrast trials
- Nephrotoxicity proxies (serum creatinine change), especially in at-risk populations.
- Incidence of contrast-induced acute kidney injury (CIAKI) or AKI definitions aligned to KDIGO.
- Hypersensitivity and immediate adverse reactions.
- Diagnostic performance metrics (image quality scoring, artifact rates).
- Workflow endpoints (injection rates, bolus timing, scan success).
- Radiation/volume efficiency is increasingly reported indirectly via protocol comparisons.
Trial archetypes likely to affect adoption of Isovue-128 in practice
- Noninferiority imaging studies comparing contrast concentration and osmolality.
- Comparative safety studies in renal impairment or high-risk comorbidity cohorts.
- Studies testing protocol optimization (dose, injection rate, volume) in CT angiography and CT abdomen/pelvis.
Clinical implication for R&D and contracting
- Contrast agents rarely require product-specific new efficacy claims for routine imaging use if safety and diagnostic performance remain within accepted ranges.
- The practical clinical differentiators that move demand are often formulary placement, procurement pricing, availability, and institution-specific adverse event experience.
Are there ongoing Isovue-128 (iopamidol 128 mg I/mL) trials right now?
Market-relevant assessment: Even when new studies enroll, they generally target comparative evidence and protocol optimization rather than new indications that would restart exclusivity. For institutional purchasing, trial results translate into adoption only if they change procurement economics or materially improve safety for high-risk protocols.
What to watch in trial disclosures
- Subgroup analyses for renal impairment.
- Allergy/hypersensitivity rates by formulation and historical rates.
- Injection protocol outcomes (timing success, image quality scores in CTA).
Why this matters for projections
- If trials support “clinical equivalence” to other low-cost iodinated alternatives, adoption tends toward the lowest net cost under contracting rather than brand retention.
What patents protect Isovue-128 and how long does exclusivity last?
Practical exclusivity posture: Isovue-128 is a mature product line. Iodinated contrast products typically face significant generic and follow-on competition once relevant composition-of-matter or protected manufacturing/formulation claims expire. In practice, procurement competition is driven by generic substitution and supply.
How exclusivity usually breaks for iodinated contrast
- Composition-of-matter and manufacturing-process patents for a specific iopamidol concentration/packaging format may expire.
- FDA exclusivity (if any) typically does not provide long tail protection for established small-molecule generics.
Impact on market projection
- Forward demand is more sensitive to price erosion than to “near-term exclusivity cliffs,” unless a remaining use or method claim is asserted against generics or a reformulation resets exclusivity.
Named product-level patent and Orange Book status
- The determinative sources for product-specific patent lists are FDA’s Orange Book entries for Isovue-128/iopamidol injection at 128 mg I/mL.
- This analysis is limited to publicly structured implications: mature exclusivity, high probability of generic substitution, and low likelihood that trial updates alone influence long-term protection.
What is the Orange Book status of Isovue-128?
Answer: Isovue-128 is an FDA-approved iopamidol injection product with an Orange Book footprint that typically includes one or more listed patents tied to the drug substance, formulation, or manufacturing. The current market reality for iopamidol contrast is characterized by broad availability including authorized generic and generic iopamidol products at comparable iodine concentrations.
Why status matters
- Orange Book listings determine Paragraph IV challenge risk and patent-filing calendars for generic manufacturers.
- With mature products, the key market question becomes whether any remaining unexpired patents block substitution for a 128 mg I/mL concentration, specific container sizes, or specific packaging.
Projection sensitivity
- If there is no remaining enforceable patent barrier, pricing pressure continues.
- If a narrow patent remains, demand may still shift but can be slowed in specific hospitals until litigation or launch outcomes clear.
When does Isovue-128 lose exclusivity and what generic entry risks exist?
High-level exclusivity timeline logic (market-driven)
- For established iopamidol injection products, exclusivity loss generally occurred years earlier, enabling generic and authorized-generic entry.
- Remaining risk is less about “new generic entry” and more about incremental market share shifts from brand to lower-cost equivalents via contract renewals and pharmacy substitution.
Paragraph IV / litigation risk profile
- For small molecules like iopamidol, generic challenges often occur near patent expiration windows.
- Once competition is already present, future filings can be fewer, and market shifts happen through standard formulary and contracting.
Generic entry risks for Isovue-128 specifically
- Container size and concentration mapping: conversion to an equivalent NDC with the same concentration matters for substitution.
- Supply and distribution: in shortages, hospitals may revert to preferred brands temporarily even if cheaper alternatives exist.
What determines whether generics expand share
- Hospital contracting terms and group purchasing organization (GPO) price tiers.
- Clinical committee protocols for renal impairment and allergy history.
- Recorded adverse event experience and pharmacovigilance signals.
How strong is the patent estate for iopamidol injection 128 mg I/mL vs competing contrast agents?
Comparative estate strength (industry pattern)
- Iodinated contrast products typically have overlapping patent strategies: formulation concentration, manufacturing methods, and container/sterility conditions.
- As the category ages, patent estates for individual brands are often weak or fully expired, leaving only narrow manufacturing or formulation claims.
Competitive patent landscape drivers
- “Same API, different concentration or packaging” can produce distinct Orange Book entries, even when the clinical differentiation is limited.
- For procurement, the presence of authorized generics can collapse effective brand protection.
Business conclusion for R&D/BD
- The biggest lever is not new product patents for Isovue-128, because the core value proposition is largely commoditized.
- The lever is supply reliability, contracting, and pharmacoeconomic positioning (net cost and service levels).
Isovue-128 market analysis: who buys it, where is demand concentrated, and what drives pricing?
Customer base
- Hospitals and imaging centers performing CT and angiography.
- Large systems with centralized purchasing and group contracts.
- Specialty providers for emergency imaging, oncology staging, and cardiovascular workflows.
Demand drivers
- Growth in CT utilization across outpatient and inpatient settings.
- Protocol intensification for CTA in cardiology and emergency medicine.
- Institutional protocols for renal-risk patients can influence iodine concentration and dose selection.
Pricing and margin structure
- Iodinated contrast markets are characterized by price compression through generic competition.
- Contracting cycles, tenders, and GPO tiers determine realized pricing more than list price.
- Brand loyalty matters less where substitution is permitted and clinically equivalent.
Market projection for Isovue-128 through 2030: base case and downside case
Projection method (market logic, not speculative trial-driven growth)
- CT utilization trend supports volumetric use of iodinated contrast products.
- Generic substitution reduces per-dose net revenue relative to historical brand pricing.
- Formulary switching occurs with contract renewals and procurement incentives.
- Supply constraints can temporarily reduce substitution and stabilize revenue.
Base case projection (most likely in mature markets)
- Volume increases with imaging utilization growth.
- Net revenue declines at a modest rate as generics capture additional formulary share.
- Brand share stabilizes where there is established supply reliability or where specific NDCs are preferred in contracts.
Downside case
- Faster substitution to lower-cost iopamidol equivalents or other iodinated contrast alternatives.
- Aggressive tender pricing by hospital systems and GPOs.
- Supply/distribution friction shifts demand to substitute products at the system level.
Upside case
- Contract wins in large networks due to service levels and assured supply.
- Product-specific scarcity reduces substitution in short windows.
- Evidence packages and protocol optimization support continued use of iopamidol at 128 mg I/mL rather than alternate concentrations.
Key metric to track
- System-level formulary share by NDC concentration and pack size.
- Average selling price (ASP) trend versus generic benchmarks for iopamidol injections.
How does Isovue-128 compare with other iopamidol and iodinated contrast brands?
Clinical equivalence is common in practice
- For many routine CT indications, iodine delivery, viscosity, and injection protocol compatibility drive use more than “brand.”
- Safety differences among nonionic iodinated monomers are usually treated as clinically comparable, with protocols and patient-specific risk determining choice.
Competitive substitute sets
- Other iopamidol concentrations (e.g., 300 mg I/mL) and alternate monomer products.
- Nonionic iodinated contrast agents from other manufacturers (different molecular agents, similar class).
Procurement comparison
- Contracts tend to select a small set of products for each imaging modality.
- Net cost and supply reliability typically win over incremental differences in evidence.
What formulation patents protect Isovue-128 and what do they cover?
Common formulation protection categories
- Sterility and container closure systems.
- Viscosity, concentration-specific properties, and manufacturing parameters that support stability.
- Emulsion/solution stability approaches and shelf-life systems.
Market impact
- Once manufacturing/process patents expire, the practical barrier drops to regulatory ANDA or permitted substitution plus supply capabilities.
- Formulation patents that remain are often narrow and do not prevent generic use of equivalent concentrations once a bioequivalent standard is met.
What FDA regulatory pathway applies to Isovue-128 generics and how does it affect launch timing?
Regulatory dynamics for mature small molecules
- Most generic competition for iopamidol follows ANDA pathways (bioequivalence requirements for solution contrast agents).
- Launch timing is typically driven by patent expiry, exclusivity status, and litigation outcomes rather than trial completion.
Switching risk
- If patent lists are limited or already expired, multiple ANDAs can launch quickly.
- If a narrow, remaining patent is enforced, generics can face a stay or delayed launch.
Key takeaways
- Isovue-128 is a mature iopamidol contrast product where clinical differentiation is typically protocol-driven and procurement-driven rather than pipeline-driven.
- Clinical trials update is not a reliable lever for brand growth; available trial literature generally supports comparative safety and imaging performance rather than new indications that restart exclusivity.
- Market projections through 2030 are most sensitive to generic substitution, hospital contracting cycles, and net price compression, not to near-term exclusivity cliffs.
- The highest business value actions are contract strategy and supply assurance, alongside monitoring of Orange Book-listed patents tied to Isovue-128 concentration and packaging that could still affect substitution timing.
FAQs
1) What is Isovue-128 used for in CT imaging and angiography?
It is used as an iodinated contrast agent for enhanced imaging in CT and related radiographic procedures, including vascular imaging workflows.
2) Do new clinical trials for iopamidol usually change product choice or formulary status?
They often inform protocol optimization and reassurance on safety, but formulary placement usually follows net pricing and supply reliability in mature contrast markets.
3) How do hospitals decide between Isovue-128 and generic iopamidol injections?
Primarily on contracted net price, availability, NDC equivalence to concentration/pack size, and institutional imaging protocol compatibility.
4) What can delay generic iopamidol competition for Isovue-128?
Any remaining unexpired Orange Book patents tied to the specific concentration/packaging, plus litigation stays or settlement-driven delay.
5) What indicators best predict Isovue-128 revenue erosion?
Trends in ASP versus iopamidol generic benchmarks, increasing formulary share for authorized generics, and aggressive GPO tender pricing outcomes.
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- ClinicalTrials.gov. (n.d.). iopamidol trials search results. U.S. National Library of Medicine. https://clinicaltrials.gov/
- Radiological and nephrotoxicity guidance literature for iodinated contrast-associated AKI (general background for endpoints and protocol considerations).
